Interferon Alpha and Retinoid Eye Drops for Ocular Lesions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular lesions such as pterygium, pinguecula, ocular dysplasia, and neoplastic disorders often require surgical intervention and are associated with recurrence and side effects, with non-surgical options like interferon alpha and retinoic acid showing low efficacy.
Innovation Solution
A combination therapy using interferon alpha and retinoids administered topically as eyedrops, which can be given sequentially or concurrently, to treat ocular lesions without the need for surgery, potentially preventing recurrence by inducing differentiation, apoptosis, and inhibiting blood vessel and fibrous tissue growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical removal is performed to treat ocular lesions, then the lesion is removed, but recurrence occurs and complications arise
Solution Approach 1:
The patent applies preliminary action by administering interferon alpha and retinoid therapy before surgical removal to reduce lesion viability and prevent recurrence. The combination therapy is given preoperatively to debilitate the lesion, making it less likely to regrow after excision, thereby addressing the recurrence problem while maintaining surgical effectiveness.
Solution Approach 2:
The patent uses composite materials by combining two different therapeutic agents - interferon alpha and retinoids - into a unified treatment regimen. This combination creates a synergistic effect where interferon alpha provides antiviral and anti-proliferative action while retinoids promote differentiation and apoptosis, together providing more effective lesion control than either agent alone, thus reducing both recurrence and complications.
2Reliability
If anti-metabolite or beta-irradiation treatment is applied to prevent pterygium regrowth, then regrowth is reduced, but side effects occur
Solution Approach 1:
The patent applies parameter changes by using interferon alpha and retinoids with different mechanisms of action compared to traditional anti-metabolites and radiation. Instead of using highly toxic agents that cause severe side effects, the patent employs agents with more favorable safety profiles that achieve regrowth prevention through antiviral, anti-proliferative, and differentiation-promoting effects, thereby maintaining reliability while reducing harmful factors.
3Reliability
If topical mitomyacin C is used to prevent lesion recurrence, then recurrence is reduced, but corrosive damage occurs
Solution Approach 1:
The patent uses interferon alpha and retinoids as intermediary agents that achieve lesion control without the direct corrosive damage of mitomycin C. These agents work through biological mechanisms - interferon alpha through antiviral and anti-proliferative pathways, and retinoids through differentiation and apoptosis induction - providing a mediating approach that prevents recurrence while avoiding the harmful corrosive effects of traditional anti-metabolites.
4Ease of operation
If non-surgical treatment with interferon alpha and retinoic acid is used, then surgery is avoided, but efficacy is low
Solution Approach 1:
The patent applies composite materials by combining interferon alpha and retinoids in a unified non-surgical treatment regimen. This combination creates synergistic effects where interferon alpha provides antiviral and anti-proliferative action while retinoids promote differentiation and apoptosis, together achieving significantly improved efficacy compared to either agent alone, thus making non-surgical treatment both easy to administer and reliably effective.
Solution Approach 2:
The patent merges two separate therapeutic approaches - interferon alpha therapy and retinoid therapy - into a single combined non-surgical treatment protocol. By merging these mechanisms of action, the patent achieves enhanced efficacy that overcomes the limitation of low effectiveness when using these agents separately, while maintaining the ease of non-surgical administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of interferon alpha and retinoids effectively treats ocular lesions, reducing the need for surgery and preventing recurrence, while causing extensive necrosis of lesions, thus facilitating surgical removal if necessary, and improving visual acuity and ocular surface health.
Implementation Method 1
potentially preventing recurrence by inducing differentiation, apoptosis, and inhibiting blood vessel and fibrous tissue growth
Implementation Method 2
potentially preventing recurrence by inducing differentiation, apoptosis, and inhibiting blood vessel and fibrous tissue growth
Implementation Method 3
potentially preventing recurrence by inducing differentiation, apoptosis, and inhibiting blood vessel and fibrous tissue growth
Implementation Method 4
causing extensive necrosis of lesions, thus facilitating surgical removal if necessary
Data Source
AI summary
Methods for the treatment of ocular lesions, particularly diseases of the surface of the eye, selected from pterygium, pinguecula, ocular dysplasia, ocular neoplastic disorders including malignancy of the limbus and eyelids in humans and animals, neurotrophic keratitis, fibrosis of conjunctival drainage blebs in glaucoma and viral disorders of the eye surface are described. Also described are uses and eyedrop formulations for the treatment of eye surface lesions.